Erlotinib has better efficacy than gefitinib in adenocarcinoma patients without EGFR-activating mutations, but similar efficacy in patients with EGFR-activating mutations

Experimental and Therapeutic Medicine

Volumn 3, Issue 2, 2012, Pages 207-213

  Wu, Wen Shuo ^a   Chen, Yuh Min ^a,b   Tsai, Chun Ming ^a   Shih, Jen Fu ^a   Chiu, Chao Hua ^a   Chou, Kun Ta ^a   Lai, Shinn Liang ^a   Wu, Chieh Hung ^a   Luo, Yung Hung ^a   Huang, Chu Yun ^a   Lee, Yu Chin ^a   Perng, Reury Perng ^a   Whang Peng, Jacqueline ^b  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Epidermal growth factor receptor; Non small cell lung cancer; Tyrosine kinase inhibitors

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB;

ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; EXON; FEMALE; HUMAN; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; POINT MUTATION; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SURVIVAL TIME; TREATMENT RESPONSE;

EID: 84855383474     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2011.383     Document Type: Article

References (29)

1. Parkin DM, Bray F, Ferlay J, et al: Global cancer statistics. CA Cancer J Clin 55: 74-108, 2005.
2. Thatcher N, Chang A, Parikh P, et al: Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 366: 1527-1537, 2005.
3. Shepherd FA, Rodrigues PJ, Ciuleanu T, et al: Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353: 123-132, 2005.
4. Chang A, Parikh P, Thongprasert S, et al: Gefitinib (IRESSA) in patients of Asian origin with refractory advanced non-small cell lung cancer: Subset analysis from the ISEL study. J Thorac Oncol 1: 847-855, 2006.
5. Kim ES, Hirsch V, Mok T, et al: Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet 372: 1809-1818, 2008.
6. Mok TS, Wu Y-L, Thongprasert S, et al: Gefitinib or carboplatin- paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361: 947-957, 2009.
7. Rosell R, Moran T, Queralt C, et al: Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 361: 958-967, 2009.
8. Zhou C, Wu YL, Chen G, et al: Efficacy results from the randomized phase III OPTIMAL (CTONG 0802) study comparing first-line erlotinib versus carboplatin (CBDCA) plus gemcitabine (GEM), in Chinese advanced non-small-cell lung cancer (NSCLC) patients (PTS) with EGFR activating mutations. Ann Oncol 21 (Suppl 8): LBA13, 2010.
9. Chen YM, Whang-Peng J and Chen CM: Review of first-line systemic therapy for metastatic non-small cell lung cancer. J Exp Clin Med 3: 116-120, 2011.
10. Janne PA and Johnson BE: Effect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome of patients with non-small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors. Clin Cancer Res 12 (Suppl 14): 4416-4420, 2006.
11. Kosaka T, Yatabe Y, Endoh H, et al: Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res 64: 8919-8923, 2004.
12. Shigematsu H, Lin L, Takahashi T, et al: Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 97: 339-346, 2005.
13. Baselga J, Rischin D, Ranson M, et al: Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J Clin Oncol 20: 4292-4302, 2002.
14. Herbst RS, Maddox AM, Rothenberg ML, et al: Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial. J Clin Oncol 20: 3815-3825, 2002.
15. Hidalgo M, Siu LL, Nemunaitis J, et al: Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol 19: 3267-3279, 2001.
16. Sharma SV, Bell DW, Settleman J, et al: EGFR growth factor mutations in lung cancer. Nat Rev Cancer 7: 169-181, 2007.
17. Fan WC, Yu CJ, Tsai CM, et al: Different efficacies of erlotinib and gefitinib in Taiwanese patients with advanced non-small cell lung cancer: a retrospective multi-center study. J Thor Oncol 6: 148-155, 2011.
18. Ciuleanu T, Stelmakh L, Cicenas S, et al: Erlotinib versus docetaxel or pemetrexed as second-line therapy in patients with advanced non-small-cell lung cancer (NSCLC) and poor prognosis: efficacy and safety results from the phase III TITAN study. Chicago Multidisciplinary Symposium in Thoracic Oncol: LBOA5, 2010.
19. Vamvakas L, Agelaki S, Kentepozidis NK, et al: Pemetrexed (MTA) compared with erlotinib (ERL) in pretreated patients with advanced non-small cell lung cancer (NSCLC): results of a randomized phase III Hellenic Oncology Research Group trial. Proc ASCO 28: 7519, 2010.
20. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors. European Organisation for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205-216, 2000.
21. Lynch TJ, Bell DW, Sordella R, et al: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small cell lung cancer to gefifitinib. N Engl J Med 350: 2129-2139, 2004.
22. Paez JG, Janne PA, Lee JC, et al: EGFR mutations in lung cancer: correlation with clinical response to gefifitinib therapy. Science 304: 1497-1500, 2004.
23. Moyer JD, Barbacci EG, Iwata KK, et al: Induction of apoptosis and cell cycle arrest by OSI-774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res 57: 4838-4848, 1997.
24. Polack VA, Savage DM, Baker DA, et al: Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinoma with OSI-774: dynamics of receptor inhibition in situ and antitumor effects in athymic mice. J Pharmacol Exp Ther 291: 739-748, 1999.
25. Cho BC, Im CK, Park MS, et al: Phase II study of erlotinib in advanced non-small cell lung cancer after failure of gefitinib. J Clin Oncol 25: 2528-2533, 2007.
26. Sharma SV, Bell DW, Settleman J, et al: Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 7: 169-181, 2007.
27. Gandhi J, Zhang J, Xie Y, et al: Alterations in genes of the EGFR signaling pathway and their relationship to EGFR tyrosine kinase inhibitor sensitivity in lung cancer cell lines. PLoS One 4: e4576, 2009.
28. Zhu CQ, Santos GC, Ding K, et al: Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol 26: 4268-4275, 2008.
29. Cappuzzo F, Ciuleanu T, Stelmakh L, et al: Erlotinib as maintenance treatment in advanced non-small cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol 11: 521-529, 2010.